

From: **SARS-CoV-2 Vaccines**

JAMA. 2021;325(13):1318-1320. doi:10.1001/jama.2021.3199

Table. SARS-CoV-2 Vaccines

Vaccine	Manufacturer	Vaccine type	Antigen	Dose	Dosage	Storage conditions	Efficacy against severe COVID-19 ^a	Overall efficacy	Current approvals
mRNA-1273	Moderna (US)	mRNA	Full-length spike (S) protein with proline substitutions	100 µg	2 Doses 28 d apart	-25° to -15 °C; 2-8 °C for 20 d; room temperature ≤12 h	100% 14 d After second dose (95% CI, not estimable to 1.00)	92.1% 14 d After 1 dose (95% CI, 68.8%-99.1%); 94.1% 14 d after second dose (95% CI, 89.3%-96.8%)	EUA: the US, EU, Canada, and UK
BNT162b2	Pfizer-BioNTech (US)	mRNA	Full-length S protein with proline substitutions	30 µg	2 Doses 21 d apart	-60° to -60 °C; 2-8 °C for 5 d; room temperature ≤2 h	88.3% After 1 dose (95% CI, 20.1%-99.7%)	57% After 1 dose (95% CI, 29.5%-68.4%); 94.6% 7 d after second dose (95% CI, 89.9%-97.3%)	EUA: the US, EU, Canada, and UK
Ad26.COV2.S	Janssen/Johnson & Johnson (US)	Viral vector	Recombinant, replication incompetent human adenovirus serotype 26 vector encoding a full-length, stabilized SARS-CoV-2 protein	5 × 10 ¹³ Viral particles	1 Dose	-20 °C; 2-8 °C; 3 mo	85% After 28 d; 100% after 49 d	72% in the US; 66% in Latin America; 57% in South Africa (at 78 d)	EUA: the US, EU, and Canada
ChAdOx1 (AZS1222)	AstraZeneca/Oxford (UK)	Viral vector	Replication deficient chimpanzee adenoviral vector with the SARS-CoV-2 S protein	5 × 10 ¹⁰ Viral particles (standard dose)	2 Doses 28 d apart (Intervals >12 wk studied)	2-8 °C for 6 mo	100% 21 d After first dose	64.1% After 1 dose (95% CI, 50.5%-73.9%); 70.4% 14 d after second dose (95% CI, 54.8%-80.6%)	EUA: WHO/Covax, the UK, India, and Mexico
NVX-CoV2373	Novavax, Inc (US)	Protein subunit	Recombinant full-length, prefusion S protein	5 µg of protein and 50 µg of Matrix-M adjuvant	2 Doses	2-8 °C for 6 mo	Unknown	89.3% in the UK after 2 doses (95% CI, 75.2%-95.4%); 60% in South Africa (95% CI, 18.9%-80.1%)	EUA application planned
CvixCoV	CureVac/GlaxoSmithKline (Germany)	mRNA	Prefusion stabilized full-length S protein of the SARS-CoV-2 virus	12 µg	2 Doses 28 d apart	2-8 °C for 3 mo; room temperature for 24 h	Unknown	Phase 3 trial ongoing	
Gam-COVID-Vac (Sputnik V)	Gammaley National Research Center for Epidemiology and Microbiology (Russia)	Viral vector	Full-length SARS-CoV-2 glycoprotein S carried by adenoviral vectors	10 ¹¹ Viral particles per dose for each recombinant adenovirus	2 Doses (first, rAd26; second, rAd5) 21 d apart	-18 °C (liquid form); 2-8 °C (directly dried) for up to 6 mo	100% 21 d After first dose (95% CI, 94.4%-100%)	87.6% 14 d After first dose (95% CI, 81.1%-91.8%); 91.1% 7 d after second dose (95% CI, 83.8%-95.1%)	EUA: Russia, Belarus, Argentina, Serbia, UAE, Algeria, Palestine, and Egypt
CoronaVac	Sinovac Biotech (China)	Inactivated virus	Inactivated CNO2 strain of SARS-CoV-2 created from Vero cells	3 µg With aluminum hydroxide adjuvant	2 Doses 14 d apart	2-8 °C; Lifespan unknown	Unknown	Phase 3 data not published; reported efficacy 14 d after dose 2: 50.38% (mild) and 78% (mild to severe) in Brazil; 55% in Indonesia; and 91.25% in Turkey	EUA: China, Brazil, Columbia, Bolivia, Brazil, Chile, Uruguay, Turkey, Indonesia, and Azerbaijan
BBIBP-CorV	Sinopharm 1/2 (China)	Inactivated virus	Inactivated HB02 strain of SARS-CoV-2 created from Vero cells	4 µg With aluminum hydroxide adjuvant	2 Doses 21 d apart	2-8 °C; Lifespan unknown	Unknown	Phase 3 data not published; unpublished reports of 79% and 86% efficacy	EUA: China, UAE, Bahrain, Serbia, Peru, and Zimbabwe

Abbreviations: EUA, Emergency Use Authorization; UAE, United Arab Emirates; WHO, World Health Organization.
^a Efficacy against severe disease, which includes COVID-19-related hospitalization, varies by age and by time after vaccination.

Table Title:

SARS-CoV-2 Vaccines Abbreviations: EUA, Emergency Use Authorization; UAE, United Arab Emirates; WHO, World Health Organization.

^a Efficacy against severe disease, which includes COVID-19–related hospitalization, varies by age and by time after vaccination.